SRPK2 and prostate cancer: Upregulation of SRPKs was publicized in many reports including studies in pancreatic cancer, breast cancer, colon cancer, prostate cancer, lung cancer, glioma, leukemia, and melanoma.24-30 SRPK1 upregulation is associated with poor prognosis of breast cancer,31 as well as with the metastasis-free and OS of lung cancer.32 This study showed the average transcript counts for which SRPK1was higher, but SRPK2 was lower in melanoma tumors when compared with the normal (Figure 1A).